Baxter's hemophilia B drug wins FDA approval

06/27/2013 | Reuters · HealthDay News · RTT News

Baxter International obtained the FDA's approval to market Rixubis, a purified protein that comes in freeze-dried powder, for routine and perioperative prevention and control of bleeding in adults with hemophilia B. The genetically engineered recombinant factor IX is the first treatment cleared for the genetic condition in more than 15 years.

View Full Article in:

Reuters · HealthDay News · RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR